The Technical Analyst
Century Therapeutics, [IPSC]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology
Century Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
6.42% $3.15
/ 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 204.51 mill |
| EPS: | -2.30 |
| P/E: | -1.370 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 64.92 mill |
| Avg Daily Volume: | 0.216 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.370 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.370 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0345 (-98.91%) $-3.12 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.79 - 3.51 ( +/- 11.52%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-22 | Russotti Gregory | Sell | 5 000 | Common Stock |
| 2024-03-07 | Pfeiffenberger Brent | Buy | 17 425 | Common Stock |
| 2024-03-07 | Pfeiffenberger Brent | Buy | 104 550 | Stock Option (right to buy) |
| 2024-03-07 | Carr Douglas | Buy | 14 000 | Common Stock |
| 2024-03-07 | Carr Douglas | Buy | 81 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 68.33 |
| Last 96 transactions |
| Buy: 23 376 623 | Sell: 13 071 716 |
Forecast:
16:00 - $3.17
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.17
Forecast 2: 16:00 - $3.17
Forecast 3: 16:00 - $3.17
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.15 (6.42% ) |
| Volume | 0.116 mill |
| Avg. Vol. | 0.216 mill |
| % of Avg. Vol | 53.65 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IPSC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Last 10 Buy Signals
Latest Press Releases
2024-04-23 07:00:00 - Press Release
Century Therapeutics To Present At Chardan's 8th Annual Genetic Medicines And Cell Therapy Manufacturing Summit
Philadelphia, april 23, 2024 (globe newswire) -- century therapeutics (nasdaq: ipsc), an innovative biotechnology company developing induced pluripotent stem cell (ipsc)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at chardan's 8th annual genetic medicines and cell therapy manufacturing summit, details of the presentations are as follows:
2024-04-11 07:00:00 - Press Release
Century Therapeutics Strengthens Position In Autoimmune Disease With Strategic Pipeline Expansion Supported By $60 Million Private Placement And Acquisition Of Clade Therapeutics
Century is pursuing additional autoimmune disease regulatory filings for its ipsc derived ink cell therapy, cnty-101, beyond calipso-1 trial in sle, based on the potential of its differentiated profile
2024-04-08 16:05:00 - Press Release
Century Therapeutics Presents New Preclinical Data Highlighting Ipsc-derived Cell Therapy Platform Technology At The 2024 American Association For Cancer Research (aacr) Annual Meeting
Philadelphia, april 08, 2024 (globe newswire) -- century therapeutics (nasdaq: ipsc), an innovative biotechnology company developing induced pluripotent stem cell (ipsc)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the company's ipsc-derived cell therapy platform was presented at the aacr annual meeting 2024. the posters highlight the company's end-to-end capabilities in ipsc reprogramming and differentiation, gene editing, synthetic biology, protein engineering and computational biology.
2024-03-19 07:00:00 - Press Release
Century Therapeutics To Present At The H.c. Wainwright 2nd Annual Cell Therapy Virtual Conference
Philadelphia, march 19, 2024 (globe newswire) -- century therapeutics (nasdaq: ipsc), an innovative biotechnology company developing induced pluripotent stem cell (ipsc)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the h.c. wainwright 2nd annual cell therapy virtual conference on tuesday, march 26th, 2024 at 1:30pm et.
2024-03-14 07:30:00 - Press Release
Century Therapeutics Reports Full Year 2023 Financial Results And Provides Business Updates
- presented initial data from phase 1 elipse-1 trial of cnty-101 in relapsed/refractory b-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that allo-evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion -
Latest News
2024-04-23 07:00:00 - GlobeNewsWire
Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows:
2024-03-19 07:00:00 - GlobeNewsWire
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET.
2024-03-07 10:56:05 - Zacks Investment Research
How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4%
The average of price targets set by Wall Street analysts indicates a potential upside of 193.4% in Century Therapeutics, Inc. (IPSC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-02-22 13:10:18 - InvestorPlace
3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024
You get what you pay for and that applies to under-$10 stocks. In many if not most cases, you're dealing with speculative ideas that have little chance of swinging higher.
2023-12-07 12:02:04 - Zacks Investment Research
Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study
Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.
2023-12-06 07:30:00 - GlobeNewsWire
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas.
2023-09-26 07:00:00 - GlobeNewsWire
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., Interim Chief Executive Officer, will participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference on Tuesday, October 3, 2023 at 9:00 AM ET.
2023-05-11 10:40:03 - Zacks Investment Research
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.53 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.66 per share a year ago.
2023-04-17 07:00:00 - GlobeNewsWire
Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., ad-interim Chief Executive Officer, will participate in a fireside chat at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit on Monday, April 24, 2023 at 10:30 AM ET.
2023-02-21 07:00:00 - GlobeNewsWire
Century Therapeutics to Present at Upcoming Investor Conferences
PHILADELPHIA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in the following investor conferences: